CAMBRIDGE, Mass., March 25 /PRNewswire-FirstCall/ --
Biogen, Inc. (Nasdaq: BGEN) today announced that Eckhard Pfeiffer, former
Compaq President and Chief Executive Officer, has been elected to Biogen's
Board of Directors, effective February 16, 2002. The election took place at
the Company's Board of Directors' meeting.
(Photo: http://www.newscom.com/cgi-bin/prnh/19990824/BIOLOGO )
Mr. Pfeiffer served as President and Chief Executive Officer of Compaq
from 1991 to 1999. During this time, he led the company through a period of
dramatic growth and revitalization. Worldwide PC market share climbed from
3.5 percent to 15.4 percent and worldwide sales soared from $3.1 billion to
more than $30 billion. Mr. Pfeiffer also serves on the boards of several
other companies, including General Motors, Hughes Electronics and LM Ericsson.
He is a member of the Advisory Board of Deutsche Bank and serves on the
Executive Board of SMU's Cox School of Business, where he received his MBA.
James C. Mullen, Biogen's President and Chief Executive Officer said,
"During his career at Compaq, Eckhard Pfeiffer has distinguished himself with
his willingness to take risks and set ambitious goals. His impact on the
worldwide personal computer business has made him one of the industry's most
respected leaders. Mr. Pfeiffer's leadership experience will be a tremendous
asset to our corporate governance as Biogen recognizes a new level of growth
and operating success."
About Biogen
Biogen, Inc., winner of the U.S. National Medal of Technology, is a
biotechnology company principally engaged in discovering and developing drugs
for human healthcare through genetic engineering. Headquartered in Cambridge,
MA, the Company's revenues are generated from U.S. and European sales of
AVONEX(R) (Interferon beta-1a) for treatment of relapsing forms of multiple
sclerosis, and from the worldwide sales by licensees of a number of products,
including alpha interferon and hepatitis B vaccines and diagnostic products.
Biogen's research and development activities are focused on novel products to
treat inflammatory and autoimmune diseases, neurological diseases, cancer,
fibrosis and congestive heart failure. The Company maintains active clinical
research programs in protein therapeutics, small molecules, genomics and gene
therapy. For copies of press releases and additional information about the
Company, please consult Biogen's Homepage on the World Wide Web at
http://www.biogen.com.
AVONEX(R) (Interferon beta-1a) is a registered trademark of Biogen, Inc.
Media Contact:
Amy McKnight
Associate Director, Public Affairs
Biogen, Inc.
Tel: (617) 679-2723
Investment Community Contact:
Christina Dillon
Manager, Investor Relations
Biogen, Inc.
Tel: (617) 679-2521
SOURCE Biogen, Inc.
 back to top
Related links:
http://www.biogen.com
Photo Notes:
NewsCom:
http://www.newscom.com/cgi-bin/prnh/19990824/BIOLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, 888-776-6555 or 212-782-2840
Company News On-Call:
http://www.prnewswire.com/comp/101550.html
CONTACT:
Media, Amy McKnight, Associate Director,
Public Affairs, +1-617-679-2723, or Investors, Christina Dillon,
Manager, Investor Relations, +1-617-679-2521, both of Biogen
|
